Asthma is a chronic disease that affects both children and adults. Due to the inflammation and tightness of the muscles around the airways, the air passage in the lungs become constricted leading to asthma. Shortness of breath, cough, chest tightness, and wheezing are the common symptoms associated with asthma. An asthma spacer is a tube-shaped holding chamber. The spacers assist in delivering the medication straight to the lungs, resulting in less drug in the mouth and throat. The asthma spacer is extremely useful when using a puffer known as a metered-dose inhaler (MDI). A spacer aids in the proper administration of aerosolized medicine. Most spacers have a one-way valve that allows the user to inhale the medication while inhaling and exhaling normally; these are also known as valve holding chambers (VHC).
The global asthma spacer market is estimated to be valued at US$ 1,637.5 million in 2021 and is expected to exhibit a CAGR of 6.4% during the forecast period (2021-2028).
Figure 1.Global Asthma Spacer Market in Terms of Value (US$ million), By Region, 2021
Increasing prevalence of respiratory diseases is projected to boost the global asthma spacer market growth over the forecast period.
The growing demand of asthma spacer is owing to increasing incidences of respiratory diseases, which can be attributed as a major driving factor for the growth of global asthma spacer market. Several factors such as allergic conditions including eczema and rhinitis (hay fever), urbanisation, exposure to tobacco smoke and viral respiratory infections are linked to an increased risk of developing asthma. For instance, in 2019, according to World Health Organization (WHO), asthma is affected around 262 million people and caused approximately 461,000 deaths. Moreover, according to Asthma U.K., in 2017, there were 77,124 hospital admissions for asthma and every 10 seconds someone has a potentially life-threatening asthma attack in the U.K.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2020 | Market Size in 2021: | US$ 1,637.5 Mn |
| Historical Data for: | 2017 to 2020 | Forecast Period: | 2021 to 2028 |
| Forecast Period 2021 to 2028 CAGR: | 6.4% | 2028 Value Projection: | US$ 2,523.1 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Trudell Medical International, PARI Respiratory Equipment, Inc., Koninklijke Philips N.V, Lupin, GlaxoSmithKline Plc., Medical Developments International, Visiomed Group Ltd., Cipla Inc., Clement Clarke international Ltd., Rossmax International Ltd., Luckys Pharma, Mediacare Equipments (India) Pvt. Ltd., Asia Connection Co., Ltd., and Laboratoire Protecsom SAS. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Figure 2.Global Asthma Spacer Market Share (%), By Spacer Type, 2021
Increasing level of air pollution leads to respiratory diseases, which is anticipated to drive the global asthma spacer market growth during the forecast period.
High demand of the asthma spacer due to rising air pollution that causes several respiratory diseases including asthma is projected to spur the global asthma spacer market growth. Exposure to a variety of environmental allergens and irritants, including indoor and outdoor air pollution is considered to increase the risk of asthma. For instance, in October 2018, according to U.S. Environmental Protection Agency, air pollution can aggravate asthma symptoms and induce asthma attacks. Severe and potentially fatal chronic respiratory diseases such as asthma that impairs the quality of life of more than 23 million Americans.
Global Asthma Spacer Market – Impact of Coronavirus (COVID-19) Pandemic
The coronavirus (COVID-19) pandemic is the most recent outbreak, which was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19 as a pandemic on March 11, 2020. According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 225 million cases and 4.63 million deaths due to coronavirus (COVID-19) were reported up till September 14, 2021, across the globe. The coronavirus (COVID-19) pandemic and lockdown in various countries across the globe has impacted the financial status of businesses in all sectors. The private healthcare sector is one of the sectors, which has been majorly impacted by the pandemic. The lockdown in various countries has created an economic burden on the private healthcare sector. Healthcare providers are facing challenges with regards to manpower, equipment, consumables, and other resources to ensure safety of patients with other diseases, and declining outpatients’ visits, among others.
Global Asthma Spacer Market: Restrain
Alternative treatment for asthma is major factor hampering the global asthma spacer market growth during the forecast period. Asthma can be treated with bronchial thermoplasty. It is a proven alternative treatment for asthma. For instance, in May 2017, Boston Scientific, a medical device developer, announced positive findings from the Post Approval Clinical Trial Evaluating Bronchial Thermoplasty (BT) in Severe Persistent Asthma (PAS2) study, which included patients treated with the Alair BT System. The findings showed that BT reduced complications in adult patients with severe persistent asthma.
Key Players
Major players operating in the global asthma spacer market include Trudell Medical International, PARI Respiratory Equipment, Inc., Koninklijke Philips N.V, Lupin, GlaxoSmithKline Plc., Medical Developments International, Visiomed Group Ltd., Cipla Inc., Clement Clarke international Ltd., Rossmax International Ltd., Luckys Pharma, Mediacare Equipments (India) Pvt. Ltd., Asia Connection Co., Ltd., and Laboratoire Protecsom SAS.
Asthma is known as chronic disease as there is no permanent treatment for it. Asthma is a disorder in which the airways constrict and swell, causing more mucus to be produced. This can make breathing difficult, resulting in coughing, a whistling sound (wheezing) on exhalation, and shortness of breath. Environmental variables such as pollen, animal dander, dust, or smoking are frequently responsible for the onset of asthma. Asthma spacers are empty tubes, generally composed of plastic. On one end, spacer fit into the mouthpiece of inhaler, and on the other end, they fit to a mouthpiece or mask. It assists the patient in getting the most out of the asthma medication with metered dosage inhaler (MDI). There are numerous brands of asthma spacers available on prescription that suit various inhalers including volumatic, aerochamber, able spacer, space chamber plus, and a2a spacer. Spacers are being used to promote medication consumption. MDI with spacers is a good substitute for nebulizers. Furthermore, nebulizer therapy is more expensive than ‘metered-dose inhaler with spacer' therapy and necessitates more equipment and maintenance to avoid contamination.
Market Dynamics
Increasing technological advancement in asthma spacer is estimated to push the global asthma spacer market growth over the forecast period. For instance, in February 2018, Trudell Medical International claims its new AeroChamber Plus Flow-Vu Anti-Static Valved Holding Chamber (VHC) spacer. This is the company’s most advanced spacer or chamber. The spacer is predominately aimed at patients who struggle with the coordination of administering with metered-dose inhaler (MDI) medicines.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients